8V8 Stock Overview
A science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Genetic Analysis AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.048 |
| 52 Week High | NOK 0.12 |
| 52 Week Low | NOK 0.017 |
| Beta | 1.88 |
| 1 Month Change | 78.95% |
| 3 Month Change | 103.42% |
| 1 Year Change | 28.65% |
| 3 Year Change | -86.69% |
| 5 Year Change | n/a |
| Change since IPO | -95.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8V8 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -10.5% | 0.4% | -0.5% |
| 1Y | 28.6% | -12.7% | 13.3% |
Return vs Industry: 8V8 exceeded the German Biotechs industry which returned -12.7% over the past year.
Return vs Market: 8V8 exceeded the German Market which returned 13.3% over the past year.
Price Volatility
| 8V8 volatility | |
|---|---|
| 8V8 Average Weekly Movement | 50.4% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 8V8's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8V8's weekly volatility (50%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 21 | Ronny Hermansen | www.genetic-analysis.com |
Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota, GA-map Dysbiosis Test, detects and characterizes dysbiosis, a disruption or imbalance in the gut microbiome, and offers an automatic comparison against a pre-defined healthy microbiota, and GA-map Analyzer, the company's software which generate test results. The company also offers GA-map Discovery, a tool to search for biomarkers, validate exploratory research findings or transfer their findings to a ready-to-use routine testing platform, GA-map Sample Collection Kit, intended for collection, transport and storage of fecal specimens for nucleic acid analyses without compromising the quality and integrity of the test results, GA-map Covid-19 Fecal Test, a kit that is CE-IVD approved non-invasive test with an easy-to-use home sampling procedure, Service laboratory, provides end-to-end microbiota profiling analysis, translating complex data into meaningful results, and Bioinformatic analysis service, offers comprehensive and sophisticated biostatistics as a service to clinical researchers.
Genetic Analysis AS Fundamentals Summary
| 8V8 fundamental statistics | |
|---|---|
| Market cap | €3.16m |
| Earnings (TTM) | -€1.30m |
| Revenue (TTM) | €1.81m |
1.7x
P/S Ratio-2.4x
P/E RatioIs 8V8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8V8 income statement (TTM) | |
|---|---|
| Revenue | NOK 20.68m |
| Cost of Revenue | NOK 3.11m |
| Gross Profit | NOK 17.57m |
| Other Expenses | NOK 32.34m |
| Earnings | -NOK 14.77m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 84.95% |
| Net Profit Margin | -71.40% |
| Debt/Equity Ratio | 20.9% |
How did 8V8 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/24 03:06 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genetic Analysis AS is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gediminas Ruginis | Norne Securities AS |